NeuroDawn Pharmaceutical is an innovative company focused on the research and development of new drugs targeting central nervous system (CNS) diseases. The company boasts a robust research team comprised of nearly a hundred experienced professionals and a comprehensive GMP production facility. NeuroDawn has successfully developed and launched a Class 1 new drug for stroke treatment and is currently advancing multiple CNS drug projects through its specialized research platforms, including the ND-S® sublingual formulation platform, the ND-M® multi-target drug development platform, and the ND-C® compound drug development platform. These platforms facilitate the progression of various drug candidates through different stages of clinical research and regulatory submission.

The company's research and development capabilities are further enhanced by its dedicated departments, which include pharmaceutical sciences, biological evaluation, and clinical research. The pharmaceutical sciences department focuses on drug discovery, synthesis, formulation, and quality standards, ensuring that innovative drug projects meet regulatory requirements for FDA and NMPA submissions. The biological evaluation department conducts extensive pharmacological studies, safety assessments, and efficacy evaluations, with a proven track record of successful clinical trials. Additionally, the clinical research department collaborates with leading hospitals to facilitate clinical studies, particularly in neurology, thereby integrating clinical resources to support comprehensive drug development efforts.

China

Neurodawn Pharmaceutical Co. Ltd. is an innovative company focusing on the development and industrialization of new drugs, with a focus on depression and anti-ischemic stroke brain cytoprotectant. They have developed drugs such as Y-2 sublingual tablet and Y-3 for depression, with a strong emphasis on efficacy and safety.

NeuroDawn Pharmaceutical

Company Details